CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.9284
8.12%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.1032
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Genprex Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.7084
Open* 2.7184
1-Year Change* 203.8%
Day's Range* 2.6984 - 2.9484
52 wk Range 0.19-1.87
Average Volume (10 days) 436.00K
Average Volume (3 months) 7.75M
Market Cap 12.28M
P/E Ratio -100.00K
Shares Outstanding 59.43M
Revenue N/A
EPS -0.61
Dividend (Yield %) N/A
Beta -0.45
Next Earnings Date Mar 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 2.9284 0.2100 7.73% 2.7184 2.9584 2.6984
Mar 27, 2024 2.7084 -0.0400 -1.46% 2.7484 2.8084 2.4984
Mar 26, 2024 2.7284 -0.1300 -4.55% 2.8584 2.8684 2.6584
Mar 25, 2024 2.8984 -0.3500 -10.77% 3.2484 3.2584 2.8784
Mar 22, 2024 3.0184 0.0600 2.03% 2.9584 3.0284 2.8984
Mar 21, 2024 2.9484 -0.0800 -2.64% 3.0284 3.0784 2.8584
Mar 20, 2024 2.9684 -0.2400 -7.48% 3.2084 3.2584 2.8684
Mar 19, 2024 3.2784 -0.4800 -12.77% 3.7584 3.8184 3.2084
Mar 18, 2024 3.9784 -0.0500 -1.24% 4.0284 4.1884 3.9584
Mar 15, 2024 4.0484 -0.0100 -0.25% 4.0584 4.2084 3.9784
Mar 14, 2024 3.9884 -0.2200 -5.23% 4.2084 4.2084 3.9384
Mar 13, 2024 3.9984 -0.1800 -4.31% 4.1784 4.2884 3.9884
Mar 12, 2024 4.1984 -0.3300 -7.29% 4.5284 4.5284 4.0984
Mar 11, 2024 4.6284 0.2600 5.95% 4.3684 4.9784 4.3684
Mar 8, 2024 4.3184 0.1400 3.35% 4.1784 4.3384 4.0584
Mar 7, 2024 4.1284 -0.0300 -0.72% 4.1584 4.2984 3.9384
Mar 6, 2024 4.3084 -0.8100 -15.83% 5.1184 5.3684 4.3084
Mar 5, 2024 4.0584 0.0000 0.00% 4.0584 4.1784 3.8084
Mar 4, 2024 4.1684 -0.2100 -4.80% 4.3784 4.5884 4.1684
Mar 1, 2024 4.4784 0.2400 5.66% 4.2384 4.6084 4.2184

Genprex, Inc. Events

Time (UTC) Country Event
Sunday, March 31, 2024

Time (UTC)

19:04

Country

US

Event

Q4 2023 Genprex Inc Earnings Release
Q4 2023 Genprex Inc Earnings Release

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

19:04

Country

US

Event

Q1 2024 Genprex Inc Earnings Release
Q1 2024 Genprex Inc Earnings Release

Forecast

-

Previous

-
Wednesday, June 26, 2024

Time (UTC)

14:00

Country

US

Event

Genprex Inc Annual Shareholders Meeting
Genprex Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 23.8307 20.6701 17.9616 10.6827 12.3635
Selling/General/Admin. Expenses, Total 12.2951 11.6767 10.6359 8.7026 11.3862
Research & Development 11.5101 8.97087 7.30292 1.96701 0.97143
Depreciation / Amortization 0.02558 0.02253 0.02278 0.01307 0.00589
Operating Income -23.8307 -20.6701 -17.9616 -10.6827 -12.3635
Net Income Before Taxes -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Net Income After Taxes -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Net Income Before Extra. Items -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Net Income -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Income Available to Common Excl. Extra. Items -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Income Available to Common Incl. Extra. Items -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Dilution Adjustment
Diluted Net Income -23.7406 -20.665 -17.9428 -10.6548 -12.3723
Diluted Weighted Average Shares 47.9521 47.0973 35.5229 16.027 13.771
Diluted EPS Excluding Extraordinary Items -0.49509 -0.43877 -0.5051 -0.6648 -0.89843
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.49509 -0.43877 -0.5051 -0.6648 -0.89843
Interest Income (Expense), Net Non-Operating 0.0901 0.00513 0.01881 0.02791 -0.0088
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue 0 0
Total Operating Expense 8.03574 9.27125 6.82163 6.11065 5.77039
Selling/General/Admin. Expenses, Total 4.05499 3.95708 3.49665 2.51112 2.83692
Research & Development 3.97692 5.31015 3.3189 3.59331 2.92693
Depreciation / Amortization 0.00384 0.00402 0.00608 0.00622 0.00654
Operating Income -8.03574 -9.27125 -6.82163 -6.11065 -5.77039
Interest Income (Expense), Net Non-Operating 0.05555 0.06847 0.0556 0.02788 0.00574
Net Income Before Taxes -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Net Income After Taxes -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Net Income Before Extra. Items -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Net Income -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Income Available to Common Excl. Extra. Items -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Income Available to Common Incl. Extra. Items -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Diluted Net Income -7.98019 -9.20277 -6.76603 -6.08278 -5.76464
Diluted Weighted Average Shares 51.979 49.4716 48.0495 47.9847 47.8934
Diluted EPS Excluding Extraordinary Items -0.15353 -0.18602 -0.14081 -0.12676 -0.12036
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.15353 -0.18602 -0.14081 -0.12676 -0.12036
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 21.4732 39.1402 27.7044 2.97664 8.84707
Cash and Short Term Investments 20.9541 38.6289 27.3197 2.00249 8.60092
Cash 20.9541 38.6289 27.3197 2.00249 8.60092
Prepaid Expenses 0.48422 0.51135 0.38455 0.17172 0.23685
Total Assets 25.085 42.8623 31.3672 3.53423 9.26896
Property/Plant/Equipment, Total - Net 0.02303 0.04861 0.03944 0.04465 0.02435
Intangibles, Net 3.56703 3.66476 3.61267 0.4912 0.37945
Other Long Term Assets, Total 0.02182 0.00869 0.01074 0.02173 0.01809
Total Current Liabilities 2.81029 1.5853 0.45072 0.51068 0.38782
Accounts Payable 0.44293 0.9732 0.19297 0.43626 0.29507
Notes Payable/Short Term Debt 0 0 0 0.07443 0.09275
Total Liabilities 2.81029 1.5853 0.45072 0.51068 0.38782
Total Long Term Debt 0 0 0 0 0
Total Equity 22.2747 41.277 30.9165 3.02355 8.88114
Preferred Stock - Non Redeemable, Net
Common Stock 0.04811 0.04787 0.04312 0.01926 0.01524
Additional Paid-In Capital 125.054 119.247 89.2956 43.4837 38.6906
Retained Earnings (Accumulated Deficit) -102.828 -78.0179 -58.4222 -40.4795 -29.8247
Total Liabilities & Shareholders’ Equity 25.085 42.8623 31.3672 3.53423 9.26896
Total Common Shares Outstanding 48.106 47.8747 43.1177 19.2638 15.2392
Total Receivables, Net 0.03485 0 0.00013 0.00066 0.0093
Accounts Receivable - Trade, Net 0.03485 0 0.00013 0.00066 0.0093
Total Inventory 0.80178
Other Current Liabilities, Total 2.36736 0.6121 0.25776
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 12.8571 12.3661 19.9421 21.4732 26.3082
Cash and Short Term Investments 11.7113 9.95568 18.0828 20.9541 25.5161
Cash 11.7113 9.95568 18.0828 20.9541 25.5161
Total Receivables, Net 0 0 0 0.03485 0.03485
Accounts Receivable - Trade, Net 0 0 0 0.03485 0.03485
Total Inventory
Prepaid Expenses 1.14576 2.41043 1.85934 0.48422 0.75728
Total Assets 16.6436 15.9111 23.3201 25.085 29.9458
Property/Plant/Equipment, Total - Net 0.01145 0.01518 0.01902 0.02303 0.02911
Intangibles, Net 3.75794 3.51268 3.33712 3.56703 3.58671
Other Long Term Assets, Total 0.01715 0.01715 0.02182 0.02182 0.02182
Total Current Liabilities 4.33813 3.86025 4.83522 2.81029 2.45731
Accounts Payable 1.17919 1.49798 2.21225 0.44293 0.68387
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 3.15894 2.36227 2.62296 2.36736 1.77344
Total Liabilities 4.33813 3.86025 4.83522 2.81029 2.45731
Total Long Term Debt 0 0 0 0 0
Total Equity 12.3055 12.0509 18.4849 22.2747 27.4885
Common Stock 0.05943 0.05198 0.05197 0.04811 0.04802
Additional Paid-In Capital 140.005 132.01 130.463 125.054 122.433
Retained Earnings (Accumulated Deficit) -127.759 -120.011 -112.031 -102.828 -94.9924
Total Liabilities & Shareholders’ Equity 16.6436 15.9111 23.3201 25.085 29.9458
Total Common Shares Outstanding 59.4298 51.9791 51.9741 48.106 48.0203
Other Equity, Total
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -23.7406 -19.5956 -17.9428 -10.6548 -12.3723
Cash From Operating Activities -17.779 -14.2849 -13.9351 -6.91872 -6.84653
Cash From Operating Activities 0.02558 0.02253 0.02278 0.01307 0.00589
Non-Cash Items 4.73194 4.27821 4.24619 3.52998 5.43538
Changes in Working Capital 1.20414 1.00995 -0.26128 0.19299 0.08454
Cash From Investing Activities 0.09773 -0.0838 -2.33725 -0.9469 -0.10332
Capital Expenditures -0.05974 -0.07244 -0.12799 -0.14512 -0.10332
Cash From Financing Activities 0.00643 25.6779 41.5895 1.26719 15.3895
Issuance (Retirement) of Stock, Net 0.00643 25.6779 41.5895 1.26719 15.3895
Net Change in Cash -17.6748 11.3092 25.3172 -6.59843 8.43967
Other Investing Cash Flow Items, Total 0.15747 -0.01136 -2.20926 -0.80178
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.20277 -23.7406 -16.9746 -10.8918 -5.30982
Cash From Operating Activities -6.93244 -17.779 -13.1926 -8.62165 -4.0717
Cash From Operating Activities 0.00402 0.02558 0.0195 0.01327 0.00673
Non-Cash Items 1.33212 4.73194 3.18436 2.0261 1.05744
Cash Taxes Paid
Cash Interest Paid
Changes in Working Capital 0.93421 1.20414 0.57811 0.23078 0.17395
Cash From Investing Activities -0.01963 0.09773 0.07805 0.0458 -0.00184
Capital Expenditures -0.01963 -0.05974 -0.03974 -0.02369 -0.00184
Other Investing Cash Flow Items, Total 0.15747 0.11779 0.06949
Cash From Financing Activities 4.08078 0.00643 0.00175 0 0
Issuance (Retirement) of Stock, Net 4.08078 0.00643 0.00175 0
Net Change in Cash -2.87128 -17.6748 -13.1128 -8.57586 -4.07354
Financing Cash Flow Items 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Genprex, Inc. Company profile

About Genprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.

Industry: Bio Therapeutic Drugs

1601 Trinity Street, Bldg. B
Suite 3.322
AUSTIN
TEXAS 78712
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

XRP/USD

0.63 Price
-1.610% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

70,500.80 Price
-0.520% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,570.17 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading